DE69918690D1 - Stabile igf/igfbp pharmazeutische formulierungen - Google Patents

Stabile igf/igfbp pharmazeutische formulierungen

Info

Publication number
DE69918690D1
DE69918690D1 DE69918690T DE69918690T DE69918690D1 DE 69918690 D1 DE69918690 D1 DE 69918690D1 DE 69918690 T DE69918690 T DE 69918690T DE 69918690 T DE69918690 T DE 69918690T DE 69918690 D1 DE69918690 D1 DE 69918690D1
Authority
DE
Germany
Prior art keywords
igfbp
igf
pharmaceutical formulations
complex
stable igf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69918690T
Other languages
English (en)
Other versions
DE69918690T2 (de
Inventor
Stephen Danko
David Passmore
Yasushi Ogawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celtrix Pharmaceuticals Inc
Original Assignee
Celtrix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharmaceuticals Inc filed Critical Celtrix Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69918690D1 publication Critical patent/DE69918690D1/de
Publication of DE69918690T2 publication Critical patent/DE69918690T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE69918690T 1998-06-01 1999-05-28 Stabile igf/igfbp pharmazeutische formulierungen Expired - Lifetime DE69918690T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/089,062 US6436897B2 (en) 1998-06-01 1998-06-01 Pharmaceutical formulations for IGF/IGFBP
US89062 1998-06-01
PCT/US1999/012173 WO1999062536A2 (en) 1998-06-01 1999-05-28 Pharmaceutical formulations for igf/igfbp

Publications (2)

Publication Number Publication Date
DE69918690D1 true DE69918690D1 (de) 2004-08-19
DE69918690T2 DE69918690T2 (de) 2005-08-18

Family

ID=22215473

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69918690T Expired - Lifetime DE69918690T2 (de) 1998-06-01 1999-05-28 Stabile igf/igfbp pharmazeutische formulierungen

Country Status (14)

Country Link
US (2) US6436897B2 (de)
EP (1) EP1082133B1 (de)
JP (1) JP2002516871A (de)
KR (1) KR20010052500A (de)
CN (1) CN1201816C (de)
AT (1) ATE270898T1 (de)
AU (1) AU4326799A (de)
BR (1) BR9910863A (de)
CA (1) CA2330925C (de)
DE (1) DE69918690T2 (de)
ES (1) ES2221456T3 (de)
HK (1) HK1040637B (de)
IL (1) IL139969A0 (de)
WO (1) WO1999062536A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
AUPR030900A0 (en) 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
ES2180416B1 (es) * 2001-03-12 2004-06-01 BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A. Procedimiento para la preparacion de mezclas de reaccion estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reaccion y kits que las contienen.
US20140186361A1 (en) 2012-09-07 2014-07-03 Coherus Biosciences, Inc. Stable Aqueous Formulations of Adalimumab
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
AU2003900481A0 (en) 2003-02-05 2003-02-20 Queensland University Of Technology Synthetic modulators of cell migration and growth
US20100143442A1 (en) 2003-02-05 2010-06-10 Queensland University Of Technology Growth factor complexes and modulation of cell migration and growth
AU2003903896A0 (en) 2003-07-28 2003-08-07 Queensland University Of Technology Skin regeneration system
ES2395035T3 (es) 2004-08-17 2013-02-07 Regeneron Pharmaceuticals, Inc. Formulaciones de antagonistas de la IL-1
EP1674113A1 (de) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Konjugate von insulinähnlichem Wachstumfaktor-1 und Poly(Ethylenglykol)
CA2899824A1 (en) * 2004-12-24 2006-06-29 Insmed, Inc. Purified rhigf-i/rhigfbp-3 complexes and their method of manufacture
EP1841474A2 (de) * 2005-01-25 2007-10-10 Wyeth Research Ireland Limited Verfahren zur diafiltrierung
CA3142945A1 (en) 2005-03-25 2006-10-05 Regeneron Pharmaceuticals, Inc. Histidine-buffered formulations of vegf antagonist
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
BRPI0715754A2 (pt) 2006-08-31 2013-07-09 Hoffmann La Roche mÉtodo para a produÇço de fator do crescimento similar Á insulina i
CA2703263C (en) 2007-11-01 2014-03-18 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
WO2010096125A1 (en) * 2008-10-29 2010-08-26 The Rockefeller University Methods and kits for treating disease by administering insulin-like growth factor binding protein-2
AU2010324554B2 (en) 2009-11-30 2014-07-31 Factor Therapeutics Limited Fibronectin: growth factor chimeras
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US20190293527A1 (en) * 2013-02-04 2019-09-26 Charm Sciences, Inc. Extraction of mycotoxins
WO2013116847A1 (en) * 2012-02-03 2013-08-08 Charm Sciences, Inc. Extraction of mycotoxins
RS58957B1 (sr) 2014-07-18 2019-08-30 Sanofi Sa Postupak za predviđanje ishoda tretmana sa afliberceptom kod pacijenta za kog se sumnja da boluje od raka
WO2016209773A1 (en) * 2015-06-22 2016-12-29 Dots Technology Corp. Improved assays and methods for allergen detection
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
KR20210157427A (ko) 2015-12-03 2021-12-28 리제너론 파마슈티칼스 인코포레이티드 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
CN108699127A (zh) * 2015-12-31 2018-10-23 西门子医疗保健诊断公司 非重组人胰岛素-样生长因子结合蛋白浓缩物
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
CN110022855B (zh) 2016-10-07 2024-07-16 瑞泽恩制药公司 室温稳定的冻干蛋白质
ES3064802T3 (en) 2016-10-21 2026-04-29 Amgen Inc Pharmaceutical formulations and methods of making the same
EP3681602B1 (de) 2017-09-11 2026-04-15 Oak Hill Bio Limited Zusammensetzungen zur verringerung des auftretens von bpd
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
KR20230113287A (ko) * 2020-10-19 2023-07-28 오크 힐 바이오 리미티드 신생아에 사용하기에 적합한 조성물
WO2023139250A1 (en) * 2022-01-24 2023-07-27 Oak Hill Bio Limited Lot release assays for igf‐1/igfbp complexes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5643867A (en) * 1992-08-26 1997-07-01 Celtrix Pharmaceuticals, Inc. Method for treating catabolic conditions
US5563046A (en) 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
ATE226958T1 (de) 1993-09-20 2002-11-15 Celtrix Pharma Behandlung von hematologischen störungen mit einem igf-1/igfbp-3 komplex
AU690941B2 (en) * 1993-11-15 1998-05-07 Celtrix Pharmaceuticals, Inc. Method of treating renal disease by administering IGF-I and IGFBP-3
AU693489B2 (en) 1993-11-15 1998-07-02 Celtrix Pharmaceuticals, Inc. Method of treating neurological disorders
US5861273A (en) 1993-12-21 1999-01-19 Celtrix Phamraceuticals, Inc. Chromosomal expression of heterologous genes in bacterial cells
US5789547A (en) 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
SE9502927D0 (sv) * 1995-08-24 1995-08-24 Pharmacia Ab Solution containing IGF-I
US5948757A (en) * 1996-03-01 1999-09-07 Celtrix Pharmaceuticals, Inc. High dose IGF-1 therapy
US5783556A (en) 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition

Also Published As

Publication number Publication date
HK1040637A1 (en) 2002-06-21
CA2330925C (en) 2010-02-09
EP1082133B1 (de) 2004-07-14
IL139969A0 (en) 2002-02-10
JP2002516871A (ja) 2002-06-11
KR20010052500A (ko) 2001-06-25
CN1201816C (zh) 2005-05-18
ES2221456T3 (es) 2004-12-16
US20030087806A1 (en) 2003-05-08
HK1040637B (zh) 2006-01-06
BR9910863A (pt) 2002-06-11
EP1082133A2 (de) 2001-03-14
WO1999062536A2 (en) 1999-12-09
US20020004478A1 (en) 2002-01-10
WO1999062536A3 (en) 2000-03-30
US6436897B2 (en) 2002-08-20
CA2330925A1 (en) 1999-12-09
AU4326799A (en) 1999-12-20
CN1315868A (zh) 2001-10-03
ATE270898T1 (de) 2004-07-15
DE69918690T2 (de) 2005-08-18

Similar Documents

Publication Publication Date Title
ATE270898T1 (de) Stabile igf/igfbp pharmazeutische formulierungen
EE04452B1 (et) Farmatseutiliselt aktiivne morfolinool ja selle kasutamine
ATE345133T1 (de) Laktose-freie, nicht-hygroskopische und wasserfreie pharmazeutische zusammensetzungen von descarboethoxyloratadin
PT1058558E (pt) Vacinas vivas recombinantes administradas com adjuvante
DE69918074D1 (de) Makrolid-formulierung mit verzögerter wirkstoffabgabe
DK2130554T3 (da) Albuminfrie faktor VIII-præparater
BR9713866A (pt) Composição farmacéutica
EE9700363A (et) Uus anesteseeriva toimega farmatseutiline segu
EE9700310A (et) N-propargüül-1-aminoindaani R-enantiomeeri, selle soolade ja kompositsioonide kasutamine
DE60015279D1 (de) Stabilisierte pharmazeutische zusammentsetzung in lyophilisierter form
DK1141015T3 (da) Insulin-lignende vækstfaktor (IGF) I-mutantvarianter
ATE463240T1 (de) Stabile zusammensetzung für eine orale dosis mit verlängerter freisetzung enthaltend pseudoephedrin and desloratadin
DK1014987T3 (da) Orale præparater med levosimendan
ATE268167T1 (de) Mehrphasige wirkstoffhaltige zubereitungsformen
DK1131331T3 (da) 13-leddede azalider og deres anvendelse som antibiotiske midler
NO995831D0 (no) Injiserbar, klar formulering av et anestetisk middel
DK1104289T3 (da) Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister
SE9402880D0 (sv) New peptide derivatives
NZ511445A (en) Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
SE9604795D0 (sv) New pharmaceutical formulation
UY27373A1 (es) Formulaciones de interferón beta-humano
DE69703308D1 (de) Lh-rh analoge mit starrer konformation, deren verwendungen und pharmazeutische zusammensetzungen
NO20006022L (no) Rekombinant human interferon <beta>-1A (IFN-<beta>-1A)- formulering
ES2131482A1 (es) Formulacion acuosa de bambuterol.
TR199900748A2 (xx) Osteinduktif protein ve dorsalize faktörünün kombinasyonunun kullanılması.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition